Only 16 requests have not yet been evaluated by the Pharmaceuticals Advisory Committee (PAC) for the inclusion of new medicines in the GHS, the Health Insurance Organisation (HIO) says, adding that the claim in an article published in the newspaper "Phileleftheros", dated 25/01/2022, that "600 medicines for serious diseases remain outside the GHS", does not correspond to reality.
Following the publication, the OAY clarifies in a statement that in 2021, the Pharmaceutical Advisory Committee (PAC) reviewed the protocols concerning 70 innovative drugs for 15 different diseases. Within 2022, the committee plans to review and create a further 15 protocols covering at least another 18 drugs, it added.
(CNA)
CNA
Contents of this article including associated images are owned by CNA
Views & opinions expressed are those of the author and/or CNA
Source
